United States - English - NLM (National Library of Medicine)

remedyrepack inc. - glipizide (unii: x7wdt95n5c) (glipizide - unii:x7wdt95n5c) - glipizide 10 mg - glipizide extended-release tablets is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. glipizide extended-release tablets are not recommended for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis. glipizide is contraindicated in patients with: - known hypersensitivity to glipizide or any of the product’s ingredients. - hypersensitivity to sulfonamide derivatives. pregnancy category c: glipizide was found to be mildly fetotoxic in rat reproductive studies at all dose levels (5 to 50 mg/kg). this fetotoxicity has been similarly noted with other sulfonylureas, such as tolbutamide and tolazamide. the effect is perinatal and believed to be directly related to the pharmacologic (hypoglycemic) action of glipizide. there are no adequate and well controlled studies in pregnant women. glipizide extended-release tablets should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. nonteratogenic e

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals inc, - glipizide (unii: x7wdt95n5c) (glipizide - unii:x7wdt95n5c) - glipizide 10 mg - glipizide extended-release tablets is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. glipizide extended-release tablets are not recommended for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis. glipizide is contraindicated in patients with: - known hypersensitivity to glipizide or any of the product’s ingredients. - hypersensitivity to sulfonamide derivatives. pregnancy category c: glipizide was found to be mildly fetotoxic in rat reproductive studies at all dose levels (5 to 50 mg/kg). this fetotoxicity has been similarly noted with other sulfonylureas, such as tolbutamide and tolazamide. the effect is perinatal and believed to be directly related to the pharmacologic (hypoglycemic) action of glipizide. there are no adequate and well controlled studies in pregnant women. glipizide extended-release tablets should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. nonteratogenic e

United States - English - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - glipizide (unii: x7wdt95n5c) (glipizide - unii:x7wdt95n5c), metformin hydrochloride (unii: 786z46389e) (metformin - unii:9100l32l2n) - glipizide 2.5 mg - glipizide and metformin hydrochloride tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. glipizide and metformin hydrochloride tablets are contraindicated in patients with:

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - glipizide (unii: x7wdt95n5c) (glipizide - unii:x7wdt95n5c), metformin hydrochloride (unii: 786z46389e) (metformin - unii:9100l32l2n) - glipizide 5 mg - glipizide and metformin hydrochloride tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. glipizide and metformin hydrochloride tablets are contraindicated in patients with: - severe renal impairment (egfr below 30 ml/min/1.73 m 2 ) (see warnings and precautions). - known hypersensitivity to glipizide or metformin hydrochloride. - acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma. diabetic ketoacidosis should be treated with insulin.

United States - English - NLM (National Library of Medicine)

kaiser foundation hospitals - glipizide (unii: x7wdt95n5c) (glipizide - unii:x7wdt95n5c), metformin hydrochloride (unii: 786z46389e) (metformin - unii:9100l32l2n) - glipizide 5 mg - glipizide and metformin hydrochloride tablets usp are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. glipizide and metformin hydrochloride tablets are contraindicated in patients with: - renal disease or renal dysfunction (e.g., as suggested by serum creatinine levels ≥ 1.5 mg/dl [males], ≥ 1.4 mg/dl [females], or abnormal creatinine clearance) which may also result from conditions such as cardiovascular collapse (shock), acute myocardial infarction, and septicemia (see warnings and precautions ). - known hypersensitivity to glipizide or metformin hydrochloride. - acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma. diabetic ketoacidosis should be treated with insulin. glipizide and metformin hydrochloride tablets should be temporarily discontinued in patients undergoing radiologic studies involving intravascular administration of iodinated contrast materials, because use of such products may result in a

United States - English - NLM (National Library of Medicine)

aurobindo pharma limited - glipizide (unii: x7wdt95n5c) (glipizide - unii:x7wdt95n5c) - glipizide 2.5 mg - glipizide extended-release tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. glipizide extended-release tablets are not recommended for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis. glipizide is contraindicated in patients with: • known hypersensitivity to glipizide or any of the product’s ingredients. • hypersensitivity to sulfonamide derivatives. risk summary available data from a small number of published studies and postmarketing experience with glipizide extended-release tablets use in pregnancy over decades have not identified any drug associated risks for major birth defects, miscarriage, or adverse maternal outcomes. however, sulfonylureas (including glipizide) cross the placenta and have been associated with neonatal adverse reactions such as hypoglycemia. therefore, glipizide extended-release tablets should be discontinued at least two weeks before expected delivery (see clinical considerations). poo

United States - English - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - glipizide (unii: x7wdt95n5c) (glipizide - unii:x7wdt95n5c) - glipizide 5 mg - glipizide tablet is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. glipizide tablets are contraindicated in patients with: 1. known hypersensitivity to the drug. 2. type 1 diabetes mellitus, diabetic ketoacidosis, with or without coma. this condition should be treated with insulin.

United States - English - NLM (National Library of Medicine)

sandoz inc - glipizide (unii: x7wdt95n5c) (glipizide - unii:x7wdt95n5c) - glipizide 5 mg - glipizide tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. glipizide tablets are contraindicated in patients with:

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals,inc. - glipizide (unii: x7wdt95n5c) (glipizide - unii:x7wdt95n5c) - glipizide 10 mg - glipizide tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. glipizide tablets are contraindicated in patients with:

United States - English - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - glipizide (unii: x7wdt95n5c) (glipizide - unii:x7wdt95n5c) - glipizide 5 mg - glipizide tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. glipizide tablets are contraindicated in patients with: - known hypersensitivity to the drug. - type 1 diabetes mellitus, diabetic ketoacidosis, with or without coma. this condition should be treated with insulin.